Analyst Conference Summary
y/y % change
See also the Vertex Pharmaceuticals Pipeline page.
Cash and equivalents balance ended at $ billion, down $ million sequentially from $1.18 billion. Debt $ million.
Cost of revenue was $ million. Royalty expense was $ million. Research and development expense was $2 million. Sales, general and administrative expenses were $ million. Restructuring benefit was $ million. Total costs and expenses were $ million, leaving operating loss of $ million. Interest expense $ million. Other expense was $ million. Income tax $ million.
More Analyst Conference Pages:
Disclaimer: My analyst call summaries may include both our condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. Before making or terminating an investment you should always verify any factual basis of your decision.
Copyright 2015 William P. Meyers